Yale Center for Analytical Sciences, Department of Biostatistics, Yale School of Public Health, 300 George Street, New Haven, CT 06520, USA.
Yale Center for Analytical Sciences, Department of Biostatistics, Yale School of Public Health, 300 George Street, New Haven, CT 06520, USA; VA Cooperative Studies Program Coordinating Center, VA Connecticut Healthcare System, 950 Campbell Avenue, West Haven, CT 06516, USA.
J Clin Epidemiol. 2018 Jun;98:16-23. doi: 10.1016/j.jclinepi.2018.02.007. Epub 2018 Feb 9.
OBJECTIVES: To investigate the association between recurrent AIDS-defining events and a semicompeting risk of death in patients with advanced, multidrug-resistant human immunodeficiency virus infection and to identify individuals at increased risk for these events using a joint frailty model. STUDY DESIGN AND SETTING: Three hundred sixty-eight patients with antiretroviral treatment failure in the Options in Management of Antiretrovirals Trial randomized to two antiretroviral treatment strategies using a 2 × 2 factorial design, intensive vs. standard and interruption vs. continuation, and followed for development of AIDS-defining events and death. RESULTS: Participants were heterogeneous for risk of AIDS-defining events and death (P < 0.001), and AIDS-defining events were strongly associated with death (P < 0.001), irrespective of treatment. The frailty model was used to classify individuals into high- and low-risk groups based on unobserved heterogeneity. Low-risk individuals were unlikely to die (0%) or have an AIDS-defining event (<4%), whereas high-risk individuals had event rates approaching 70%. About one-third of high-risk individuals had accelerated mortality, all who died before experiencing an AIDS-defining event. High-risk was associated with being immunocompromised and higher predicted 5-year mortality. CONCLUSION: The joint frailty model permits classification of individuals into risk groups based on unobserved heterogeneity that may be identifiable based on observed covariates, providing advantages over the traditional Cox model.
目的:调查在晚期、多药耐药人类免疫缺陷病毒感染患者中,复发性艾滋病定义事件与死亡半竞争风险之间的关联,并使用联合脆弱性模型确定这些事件风险增加的个体。
研究设计和地点:368 名在 Options in Management of Antiretrovirals 试验中因抗逆转录病毒治疗失败而随机分配到两种抗逆转录病毒治疗策略的患者,采用 2×2 析因设计,强化与标准治疗以及中断与继续治疗,并随访艾滋病定义事件和死亡的发生。
结果:参与者在艾滋病定义事件和死亡的风险方面存在异质性(P<0.001),并且无论治疗如何,艾滋病定义事件与死亡密切相关(P<0.001)。脆弱性模型用于根据未观察到的异质性将个体分类为高风险和低风险组。低风险个体不太可能死亡(0%)或发生艾滋病定义事件(<4%),而高风险个体的事件发生率接近 70%。约三分之一的高风险个体有加速死亡的情况,所有这些人在发生艾滋病定义事件之前都已经死亡。高风险与免疫功能受损和较高的预测 5 年死亡率相关。
结论:联合脆弱性模型允许根据未观察到的异质性将个体分类为风险组,这种异质性可能基于观察到的协变量进行识别,与传统的 Cox 模型相比具有优势。
Cochrane Database Syst Rev. 2022-2-1
Stat Methods Med Res. 2018-7-31
Circ Cardiovasc Qual Outcomes. 2016-5
Int J Epidemiol. 2015-2
J Acquir Immune Defic Syndr. 2013-2-1
J Am Geriatr Soc. 2010-3-22